miR-99 family of microRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation

Cancer Research

Volumn 71, Issue 4, 2011, Pages 1313-1324

  Sun, Dandan ^a   Lee, Yong Sun ^a   Malhotra, Ankit ^a   Kim, Hak Kyun ^a   Matecic, Mirela ^a   Evans, Clive ^b   Jensen, Roderick V ^c   Moskaluk, Christopher A ^a   Dutta, Anindya ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 99; PROSTATE SPECIFIC ANTIGEN; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROARRAY ANALYSIS; MICRORNAS; MULTIGENE FAMILY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA INTERFERENCE;

EID: 79951828224     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1031     Document Type: Article

References (47)

1. Tolia NH, Joshua-Tor L. Slicer and the argonautes. Nat Chem Biol 2007;3:36-43.
2. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009;4:199-227.
3. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: profile, profile, profile. Int J Cancer 2008;122:969-77. (Pubitemid 351213993)
4. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009;16:206-16.
5. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003;10:209-16. (Pubitemid 36758650)
6. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 2006;99:362-72. (Pubitemid 44435554)
7. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 2008;3:e4029.
8. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008;14:417-24. (Pubitemid 351397806)
9. Musiyenko A, Bitko V, Barik S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7gene, regulates protein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med 2008;86:313-22.
10. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 2007;104:19983-8.
11. Gandellini P, Folini M, Zaffaroni N. Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol Med 2009;15:381-90.
12. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A. Muscle-specific microRNA miR-206 promotes muscle differentiationJ Cell Biol 2006;174:677-87.
13. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001;294:858-62. (Pubitemid 33032104)
14. Li Y, Bor YC, Misawa Y, Xue Y, Rekosh D, Hammarskjold ML. An intron with a constitutive transport element is retained in a Tap messenger RNA. Nature 2006;443:234-7. (Pubitemid 44387614)
15. Machida YJ, Chen Y, Machida Y, Malhotra A, Sarkar S, Dutta A. Targeted comparative RNA interference analysis reveals differential requirement of genes essential for cell proliferation. Mol Biol Cell 2006;17:4837-45. (Pubitemid 44665752)
16. Available from: http://microrna.sanger.ac.uk/sequences/. Accessed August 2007.
17. Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). Genes Dev 2009;23:2639-49.
18. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006;5:24.
19. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8. (Pubitemid 40839735)
20. Jackson RJ, Standart N. How do microRNAs regulate gene expression? Sci STKE 2007;2007:re1.
21. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol Cell 2006;21:533-42. (Pubitemid 43228008)
22. Nottrott S, Simard MJ, Richter JD. Human let-7a miRNA blocks protein production on actively translating polyribosomes. Nat Struct Mol Biol 2006;13:1108-14. (Pubitemid 44885922)
23. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005;309:1573-6. (Pubitemid 41266485)
24. Kong YW, Cannell IG, de Moor CH, Hill K, Garside PG, Hamilton TL, et al. The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. Proc Natl Acad Sci U S A 2008;105:8866-71.
25. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008;68:6162-70.
26. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008;27:1788-93. (Pubitemid 351380263)
27. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67:6130-5. (Pubitemid 47037493)
28. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61. (Pubitemid 43271657)
29. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14:2690-5.
30. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR- 184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008;14:2588-92.
31. Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, Osada H, et al. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chromosomes Cancer 2008;47:810-8.
32. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008;455:64-71.
33. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-8. (Pubitemid 32691931)
34. Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 1998;160:220-9. (Pubitemid 29479466)
35. Periyasamy S, Hinds T Jr., Shemshedini L, Shou W, Sanchez ER. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene 2009;29:1691-1701.
36. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995;1:1089-94.
37. Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007;67:312-29.
38. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 1998;77:887-94. (Pubitemid 28378138)
39. LeRoy G, Loyola A, Lane WS, Reinberg D. Purification and characterization of a human factor that assembles and remodels chromatin. J Biol Chem 2000;275:14787-90. (Pubitemid 30337188)
40. Sheu JJ, Choi JH, Yildiz I, Tsai FJ, Shaul Y, Wang TL, et al. The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res 2008;68:4050-7.
41. van de Wijngaart DJ, Dubbink HJ, Molier M, de Vos C, Trapman J, Jenster G. Functional screening of FxxLF-like peptide motifs identifies SMARCD1/BAF60 a as an androgen receptor cofactor that modulates TMPRSS2 expression. Mol Endocrinol 2009;23:1776-86.
42. Hsiao PW, Fryer CJ, Trotter KW, Wang W, Archer TK. BAF60 a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation. Mol Cell Biol 2003;23:6210-20. (Pubitemid 37013098)
43. Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev 2009;23:1313-26.
44. Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M, et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res 2009;69:7466-72.
45. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, GhoshPM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008;27:7106-17.
46. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005;65:2825-31. (Pubitemid 40490085)
47. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010;24:447-63.